Bristol-Myers Squibb Co. agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash, heating up the competition among drugmakers to develop diabetes treatments.
Kansas City Star: Business, Kansas City Star: Business
Sun, 07/01/2012 - 9:39am
Bristol-Myers Squibb Co. agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash, heating up the competition among drugmakers to develop diabetes treatments.